Kallianos Anastasios, Zarogoulidis Paul, Ampatzoglou Fotini, Trakada Georgia, Gialafos Elias, Pitsiou Georgia, Pataka Athanasia, Veletza Lemonia, Zarogoulidis Konstantinos, Hohenforst-Schmidt Wolfgang, Petridis Dimitris, Kioumis Ioannis, Rapti Aggeliki
2nd Pulmonary Department, Sotiria Chest Diseases Hospital, Athens, Greece.
Pulmonary Department-Oncology Unit, "G Papanikolaou" General Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Patient Prefer Adherence. 2015 Aug 18;9:1179-88. doi: 10.2147/PPA.S86465. eCollection 2015.
Pulmonary function tests (PFTs) do not always predict functional limitations during exercise in sarcoidosis. Cardiopulmonary exercise testing (CPET) may facilitate the recognition of exercise intolerance in these patients.
As relevant data in sarcoid patients are limited, the aim of the study reported here was to assess exercise capacity impairment during a maximal CPET and to evaluate potential correlations with PFT measurements and radiological stages of the disease.
A total of 83 sarcoid patients consecutively referred for evaluation of exertional dyspnea over a 3-year period were studied retrospectively with PFTs, including spirometry, diffusing capacity of the lung for carbon monoxide (DLCO) and lung volumes, and CPET using standard protocol. Patients were grouped according to their radiological stages: Stage I (n=43), Stages II-III (n=31), and Stage IV (n=9).
Forced expiratory volume in 1 second, forced vital capacity, and total lung capacity were mildly impaired only in Stage IV (means ± standard deviation: 72.44±28.00, 71.33±26.70, and 59.78±21.72, respectively), while DLCO was mildly and moderately reduced in Stages II-III and IV (72.68±14.13 and 51.22±18.50, respectively) and differed significantly between all stages (I vs II-III: P=0.003, I vs IV: P=0.003, and II-III vs IV: P=0.009). Exercise capacity (as expressed by peak oxygen consumption <84% predicted) was decreased in 53% of patients (Stage I: 48%, Stages II-III: 52%, Stage IV: 78%); however, significant differences were noticed only between Stages I and IV (P=0.0025). Of note, significant correlations were found between peak oxygen consumption and DLCO (P=0.0083), minute ventilation (P<0.0001), oxygen pulse (P<0.0001), lactate threshold (P<0.0001), and peak ventilatory threshold (P<0.0001).
CPET could be considered a useful tool in exercise intolerance evaluation in sarcoid patients with mild PFT abnormalities. Exercise limitation in sarcoidosis may be attributed to both ventilatory and cardiocirculatory impairment.
肺功能测试(PFTs)并不总能预测结节病患者运动时的功能受限情况。心肺运动测试(CPET)可能有助于识别这些患者的运动不耐受情况。
由于结节病患者的相关数据有限,本文报告的研究目的是评估最大CPET期间的运动能力损害,并评估其与PFT测量值及疾病放射学分期之间的潜在相关性。
回顾性研究了连续3年因劳力性呼吸困难前来评估的83例结节病患者,进行了PFTs,包括肺活量测定、肺一氧化碳弥散量(DLCO)和肺容积测定,并采用标准方案进行CPET。患者根据放射学分期分组:I期(n = 43)、II - III期(n = 31)和IV期(n = 9)。
仅IV期患者的1秒用力呼气量、用力肺活量和肺总量轻度受损(均值±标准差分别为:72.44±28.00、71.33±26.70和59.78±21.72),而DLCO在II - III期和IV期轻度及中度降低(分别为72.68±14.13和51.22±18.50),且各期之间差异显著(I期与II - III期:P = 0.003,I期与IV期:P = 0.003,II - III期与IV期:P = 0.009)。53%的患者运动能力下降(以预测的峰值耗氧量<84%表示)(I期:48%,II - III期:52%,IV期:78%);然而,仅I期和IV期之间存在显著差异(P = 0.0025)。值得注意的是,发现峰值耗氧量与DLCO(P = 0.0083)、分钟通气量(P<0.0001)、氧脉搏(P<0.0001)、乳酸阈值(P<0.0001)和峰值通气阈值(P<0.0001)之间存在显著相关性。
对于PFT轻度异常的结节病患者,CPET可被视为评估运动不耐受的有用工具。结节病患者的运动受限可能归因于通气和心脏循环功能障碍。